# US Plasma Therapy Market > US Plasma Therapy Market Research Report: Size, Share, Trend Analysis By Applications (Orthopedics, Dermatology, Dental, Cardiology), By Types (Platelet Rich Plasma, Platelet Rich Fibrin, Bone Marrow Aspirate), By End Use (Hospitals, Ambulatory Surgical Centers, Clinics) and By Procedure Type (Invasive, Non-invasive) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.32% - **2024:** $ 1,183.35 Million - **2025:** $ 1,293.64 Million - **2035:** $ 3,154.1 Million - **Key Players:** Grifols (ES), Takeda (JP), CSL Behring (AU), Octapharma (CH), Kedrion (IT), Biotest (DE), LFB (FR), Hualan Biological Engineering (CN) **Report ID:** MRFR/Pharma/16123-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-plasma-therapy-market-17651 --- ## Market Summary ## **US Plasma Therapy Market Overview** As per MRFR analysis, the US Plasma Therapy Market Size was estimated at 0.93 (USD Billion) in 2023. The US Plasma Therapy Market Industry is expected to grow from 1.3(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The US Plasma Therapy Market CAGR (growth rate) is expected to be around 9.421% during the forecast period (2025 - 2035). ### **Key US Plasma Therapy Market Trends Highlighted** The US Plasma Therapy Market is witnessing significant growth fueled by the increasing adoption of regenerative medicine and a heightened focus on innovative treatment options for various medical conditions. One of the key market drivers is the rising prevalence of chronic diseases and orthopedic conditions, which has led to a growing demand for effective therapies like plasma therapy. Health practitioners in the US are increasingly recognizing the benefits of utilizing platelet-rich plasma for treatment, especially in sports medicine and cosmetic procedures, adding to the therapy's appeal. Additionally, advancements in technology are paving the way for improved processing techniques for plasma extraction, enhancing the safety and efficacy of treatments. The US healthcare landscape is also supportive of plasma therapies, as regulatory bodies streamline the approval process for such innovations, thus promoting market growth. Opportunities exist in the development of new applications of plasma therapy, particularly in treating conditions like osteoarthritis and tendon injuries. The ongoing research efforts, including clinical trials, present avenues for expanding the therapeutic potential of plasma therapy, highlighting its versatility and reliability. Recent trends indicate a shift towards more personalized and minimally invasive treatment methods, which aligns with patient preferences in the US. The healthcare industry is moving towards integrating plasma therapy into standard treatment protocols, reflecting not only its therapeutic effectiveness but also the growing patient awareness and demand for such solutions. Furthermore, physician training programs are increasingly incorporating plasma therapy, ensuring that practitioners are well-equipped to offer these advanced treatment options to their patients continuously. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Plasma Therapy Market Drivers** ### **Increasing Acceptance of Plasma Therapy in Medical Treatments** The US **[Plasma Therapy Market](../../../reports/plasma-therapy-market-10733)**Industry is witnessing a significant increase in the acceptance of plasma therapy across various medical fields, including orthopedics, dermatology, and oncology. The American Academy of Orthopaedic Surgeons indicates that over 2 million Americans undergo orthopedic procedures each year, with a growing trend towards minimally invasive techniques that include plasma therapy. Additionally, the approval of innovative therapy products by the Food and Drug Administration, such as platelet-rich plasma treatments for injury healing and surgery recovery, is paving the way for broader market adoption. This growing acceptance is likely to contribute to the projected growth in the US Plasma Therapy Market Industry, with an expected compound annual growth rate of 9.421%. Moreover, the National Institutes of Health reports that conditions treated by plasma therapy have seen an increase in patient outcomes, which bolsters the credibility and demand for such therapies in the US healthcare system. ### **Rising Incidence of Chronic Diseases** The US Plasma Therapy Market Industry is being driven by the rising incidence of chronic diseases, particularly in conditions such as arthritis, diabetes, and heart disease. The Centers for Disease Control and Prevention report that approximately 60% of adults in the US have at least one chronic disease, showing a clear need for innovative treatment solutions. Platelet-rich plasma therapy, an effective intervention to manage pain and promote healing in musculoskeletal injuries, is becoming more prominent in clinical practices. This high prevalence of chronic conditions suggests an increased demand for effective treatment modalities, ultimately fueling growth in the US Plasma Therapy Market Industry. ### **Technological Advancements in Plasma Processing** Technological advancements in plasma processing and the development of new methodologies are significant drivers of growth in the US Plasma Therapy Market Industry. Innovations in blood extraction and plasma separation techniques are enhancing the effectiveness and safety of plasma therapies. Regulatory advancements have encouraged investment in Research and Development by companies such as Terumo Blood and Cell Technologies and CSL Behring, leading to more efficient processing systems and improved product offerings. According to the American Red Cross, there has been a 10% increase in blood donations over the past five years, which further increases the availability of plasma for therapeutic applications. These technological advancements are thus essential for meeting the growing demand for plasma therapies in the US market. ### **Increased Focus on Regenerative Medicine** There is an increased focus on regenerative medicine within the healthcare sector, which is significantly impacting the US Plasma Therapy Market Industry. This field emphasizes healing and tissue regeneration, where plasma therapy plays a critical role. The National Institutes of Health reports that regenerative medicine is projected to grow to $50 billion by 2026, indicating a strong trend toward therapies that enhance the body's natural healing processes. Major research institutions like Johns Hopkins University are investing heavily in regenerative medicine research, leading to novel applications of plasma therapy in treating conditions such as sports injuries and degenerative diseases. This shift towards regenerative approaches further stimulates the demand for plasma therapies in the United States. ## **US Plasma Therapy Market Segment Insights** ### **Plasma Therapy Market Application Insights** The US Plasma Therapy Market focuses on various applications that leverage the therapeutic potential of plasma-derived products. Among these applications, Orthopedics stands out due to the increasing prevalence of musculoskeletal disorders, which has catalyzed the adoption of plasma therapy for tissue healing and regeneration. The utilization of platelet-rich plasma (PRP) injections in Orthopedics is gaining traction, as these treatments are known to expedite recovery times and enhance the healing of injuries, particularly in the knee, shoulder, and other joints. In Dermatology, the use of plasma therapy has emerged as a promising avenue for addressing skin conditions, as well as improving aesthetic outcomes. Procedures such as PRP facials have become popular for their potential to rejuvenate the skin, enhance texture, and reduce the signs of aging. This segment benefits from a heightened consumer awareness of non-invasive treatments, further driving interest in plasma-based solutions. The Dental field is also witnessing an uptick in the use of plasma therapy, particularly in procedures aimed at promoting healing after oral surgeries or tooth extractions. Plasma-derived products are considered valuable in improving the outcomes of dental procedures, as they may help reduce recovery times and the likelihood of complications, thus gaining acceptance among dental professionals. Cardiology is another critical area where plasma therapy is gaining attention, particularly for its potential role in enhancing heart function and recovery after cardiac events. The healing properties of plasma products may provide innovative ways to support cardiovascular health, addressing a significant and growing concern in the US as lifestyle-related heart diseases continue to rise. Overall, the segmentation of the US Plasma Therapy Market across these applications reflects a broader trend toward personalized, targeted therapies that harness the natural healing capabilities of the body. The potential for plasma therapies to complement existing medical treatments presents major opportunities for growth and innovation in these fields, affirming their importance in the landscape of modern medicine. As the market continues to evolve, ongoing research and clinical trials will likely shape the adoption levels and applications of plasma therapies across these critical health domains. The expansion of these applications could be further supported by favorable regulatory conditions and increasing investments in research and development activities aimed at enhancing clinical understanding and efficacy. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Plasma Therapy Market Type Insights** The US Plasma Therapy Market is characterized by a diverse range of types, with Platelet Rich Plasma (PRP), Platelet Rich Fibrin (PRF), and Bone Marrow Aspirate being notable segments. PRP has gained significant traction in the field of regenerative medicine due to its ability to promote healing and tissue regeneration, making it a preferred option in various clinical applications, including orthopedics and dermatology. On the other hand, PRF, which provides a higher concentration of growth factors than PRP, has been recognized for its effectiveness in tissue repair, especially in dental and surgical settings, often leading to reduced healing times. Meanwhile, Bone Marrow Aspirate, known for its rich stem cell content, plays a crucial role in treating orthopedic injuries and chronic conditions, offering considerable potential for joint repair and enhancement of recovery processes. The growth of these segments is supported by advancements in technologies and increased acceptance of non-invasive treatments among patients in the US. This market diversity highlights the importance of tailored therapies for specific medical needs, driving innovation and improved patient outcomes in the US Plasma Therapy Market. ### **Plasma Therapy Market End Use Insights** The US Plasma Therapy Market is characterized by diverse end use applications, which significantly influence its growth trajectory. Hospitals play a critical role as they cater to a substantial volume of patients requiring plasma therapies for various medical conditions, particularly in emergency and surgical settings. Ambulatory Surgical Centers are gaining traction due to their ability to provide specialized plasma treatments in a more efficient and cost-effective manner, appealing to patients looking for alternatives to traditional hospital settings. Clinics are also pivotal in delivering outpatient plasma therapy services, offering tailored treatment plans to meet individual patient needs. The increasing prevalence of chronic diseases and rising geriatric population in the US are prime drivers enhancing the demand for plasma therapy across these end use categories. Furthermore, advancements in plasma extraction and treatment technologies present significant opportunities for growth in this market. As these end use segments evolve, they will continue to shape the dynamics of the US Plasma Therapy Market, impacting market growth and driving innovations in patient care. ### **Plasma Therapy Market Procedure Type Insights** The US Plasma Therapy Market is making significant strides within the healthcare industry, particularly in its Procedure Type segment, which encompasses both invasive and non-invasive approaches. The demand for these procedures is on the rise, driven by their effectiveness in treating a variety of conditions, including musculoskeletal disorders and skin rejuvenation. Invasive procedures, known for their direct application of plasma, often yield immediate results, making them popular among patients seeking quick recovery solutions. Conversely, non-invasive methods are seeing increased traction due to their appeal for patients wary of surgical interventions, providing substantial benefits with minimal downtime. This segmentation reflects a growing trend towards personalized patient care, as practitioners increasingly tailor treatments to individual needs. The US Plasma Therapy Market is positioned to adapt as healthcare providers and patients alike prioritize safety, efficacy, and convenience in treatment options. By focusing on these procedures, the market is expected to capitalize on the ongoing advancements in technology and research, creating a dynamic environment for future growth and innovation. Key factors such as an aging population, increasing healthcare expenditure, and a rise in chronic diseases contribute to the evolving landscape of the US Plasma Therapy Market. ## **US Plasma Therapy Market Key Players and Competitive Insights** The US Plasma Therapy Market has become increasingly competitive, driven by various factors including rising demand for plasma-derived therapies, advancements in technology, and an expanding patient population in need of specific treatments. The market features a complex landscape characterized by numerous players, each vying for market share by leveraging their unique strengths and capabilities. This competition is further intensified by ongoing research and development initiatives aiming to improve existing therapies and create new applications for plasma products. Key players are focusing on strategic partnerships, collaborations, and innovations to enhance their market presence and address an array of therapeutic areas that plasma therapy covers. Octapharma has established a significant footprint in the US Plasma Therapy Market, primarily recognized for its high-quality plasma products. The company's strengths lie in its robust manufacturing capabilities and a strong commitment to research and development, which ensures a consistent supply of innovative therapies tailored to meet the needs of patients. Octapharma’s presence in the US is bolstered by its extensive distribution network, which enables it to deliver critical therapies efficiently. Furthermore, its dedication to patient safety and product efficacy has fostered trust among healthcare providers and patients alike, solidifying its competitive position in an increasingly crowded market. LFB Group also plays a vital role in the US Plasma Therapy Market, focusing on the development and production of a diverse range of plasma-derived medicinal products, including immunoglobulins and clotting factors. The company’s strengths include its advanced biotechnology platform and commitment to quality, ensuring that its products meet stringent regulatory standards. Additionally, LFB Group is actively pursuing growth strategies through mergers and acquisitions, which enhance its market presence and expand its product offerings in the US. By fostering strategic partnerships and investing in innovation, LFB Group positions itself to respond quickly to market demands, thereby reinforcing its status as a prominent player in the US plasma therapy landscape. ### **Key Companies in the US Plasma Therapy Market Include** The US Plasma Therapy Market has seen significant developments recently, particularly with the ongoing research into the efficacy of convalescent plasma for treating various conditions, including COVID-19. Companies like Grifols and CSL Behring have expanded their manufacturing capabilities to meet the rising demand for immunoglobulin therapies. Additionally, in July 2023, Takeda Pharmaceuticals announced its plan to acquire a competitor, enhancing its product portfolio in plasma-derived therapies. Meanwhile, Abbott launched a new diagnostic test in August 2023 to streamline blood component collection, aiding firms like Octapharma and LFB Group in optimizing their processes. With increasing investments in Research and Development, sectors involving Plasma Therapy are projected to grow, alongside rising valuations due to the surge in autoimmune diseases and hemophilia treatment requirements. Over the past couple of years, regulations have tightened around plasma source management, impacting operations across the market. In November 2022, the FDA released new guidelines affecting the quality and safety standards for plasma collections, elevating operational benchmarks for companies like Kedrion Biopharma and AMAG Pharmaceuticals. These dynamics reflect a continually evolving landscape in the US Plasma Therapy Market. ## **US Plasma Therapy Market Segmentation Insights** ### **Plasma Therapy Market Application Outlook** ### **Plasma Therapy Market Type Outlook** ### **Plasma Therapy Market End Use Outlook** ### **Plasma Therapy Market Procedure Type Outlook** ## Market Drivers ### Supportive Reimbursement Policies Supportive reimbursement policies are emerging as a key driver for the plasma therapy market. As insurance companies begin to recognize the value of plasma therapy, more treatment options are becoming covered under various plans. This shift is likely to alleviate financial barriers for patients, making plasma therapy more accessible. With an increasing number of insurers providing coverage, the market could see a significant uptick in patient participation. The alignment of reimbursement policies with the growing body of evidence supporting plasma therapy's effectiveness may further enhance its adoption in clinical practice. ### Expansion of Clinical Applications The plasma therapy market is benefiting from the expansion of clinical applications across diverse medical specialties. Initially popular in orthopedics, plasma therapy is now being explored for use in dermatology, dentistry, and sports medicine. This diversification is likely to attract a wider range of patients and healthcare providers, thereby driving market growth. As research continues to validate the efficacy of plasma therapy in treating various conditions, the market could see an increase in investment and innovation. The potential for new applications may further solidify plasma therapy's position in the healthcare landscape. ### Growing Awareness of Regenerative Medicine Awareness surrounding regenerative medicine is on the rise, significantly impacting the plasma therapy market. Educational initiatives and media coverage are informing both healthcare professionals and patients about the benefits of plasma therapy. This increased awareness is fostering a more informed patient base that actively seeks out these innovative treatments. As a result, the market is expected to witness a surge in demand, with projections indicating a potential market value exceeding $5 billion by 2030. The growing recognition of plasma therapy as a viable treatment option is likely to enhance its adoption across various medical fields. ### Increasing Demand for Non-Surgical Treatments The plasma therapy market is experiencing a notable increase in demand for non-surgical treatment options. Patients are increasingly seeking alternatives to invasive procedures, which can entail longer recovery times and higher risks. Plasma therapy, known for its regenerative properties, offers a minimally invasive solution that appeals to a broad demographic. According to recent estimates, the market is projected to grow at a CAGR of approximately 10% over the next five years. This shift towards non-surgical interventions is likely to drive the plasma therapy market, as healthcare providers expand their offerings to meet patient preferences and improve outcomes. ### Technological Innovations in Treatment Delivery Technological innovations are playing a crucial role in enhancing the efficacy and accessibility of plasma therapy. Advances in equipment and techniques for extracting and administering plasma are improving treatment outcomes and patient experiences. For instance, the development of automated systems for plasma extraction is streamlining procedures, making them more efficient. This trend is likely to bolster the plasma therapy market, as healthcare facilities adopt these technologies to provide better care. The integration of technology into treatment protocols may also lead to increased patient satisfaction and higher rates of therapy adoption. ## Future Outlook The [Plasma Therapy Market](https://www.marketresearchfuture.com/reports/plasma-therapy-market-10733) is projected to grow at a 9.32% CAGR from 2025 to 2035, driven by technological advancements, increasing applications, and rising demand for regenerative medicine. **New opportunities:** - Development of specialized plasma collection centers in urban areas. Partnerships with healthcare providers for integrated plasma therapy solutions. Investment in R&D for innovative plasma-derived products targeting chronic diseases. By 2035, the plasma therapy market is expected to achieve substantial growth, reflecting its critical role in modern healthcare. ## Segment Insights ### By Application: Orthopedics (Largest) vs. Dermatology (Fastest-Growing) In the US [plasma therapy market](https://www.marketresearchfuture.com/reports/plasma-therapy-market-10733), Orthopedics holds the largest market share, primarily driven by the rising prevalence of musculoskeletal disorders and the increasing adoption of innovative treatment protocols. Dermatology follows closely, attributing its growth to heightened awareness and demand for advanced skincare solutions, which utilize plasma therapy for various skin conditions. The US plasma therapy market exhibits robust growth trends across its application segments, fueled by technological advancements and an expanding range of therapeutic uses. Dermatology is recognized as the fastest-growing area, propelled by increasing cosmetic procedures and an aging population that seeks regenerative treatments. Moreover, the shift towards minimally invasive procedures is further accelerating the adoption of plasma therapy in multiple applications. Orthopedics (Dominant) vs. Dermatology (Emerging) Orthopedics remains the dominant application segment within the US plasma therapy market, leveraging its effectiveness in treating joint injuries, arthritis, and post-surgical recovery. The segment is characterized by a well-established presence in clinical settings and a strong endorsement from orthopedic specialists. Conversely, Dermatology is emerging rapidly, showcasing its potential in aesthetic treatments and conditions like alopecia and acne. This segment is experiencing increased traction due to innovative applications in facial rejuvenation and wound healing, making it a notable area of growth. The integration of plasma therapy in dermatology is markedly enhancing patient outcomes, with practitioners advocating for its efficacy in rejuvenating skin and promoting healing. ### By Type: Platelet Rich Plasma (Largest) vs. Platelet Rich Fibrin (Fastest-Growing) The US plasma therapy market showcases a diverse distribution among different types, with Platelet Rich Plasma (PRP) commanding the largest share due to its established efficacy in various therapeutic applications. On the other hand, Platelet Rich Fibrin (PRF) is gaining recognition and traction in recent years, leading to a burgeoning market presence, particularly in regenerative medicine. Bone Marrow Aspirate, while important, holds a smaller portion of the market compared to these two main contenders. Growth trends in the US plasma therapy market are being driven by increasing acceptance and awareness of plasma therapies among healthcare professionals and patients. Innovative advancements in technology and the ability to customize treatment regimens have contributed significantly to the rise of PRF as the fastest-growing segment. Furthermore, collaborations between research institutions and healthcare providers are paving the way for more validated applications of plasma therapies, enhancing patient outcomes and driving market expansion. Platelet Rich Plasma (Dominant) vs. Bone Marrow Aspirate (Emerging) Platelet Rich Plasma (PRP) remains the dominant force in the US plasma therapy market, revered for its versatility in treating a range of conditions from orthopedic injuries to aesthetic procedures. Its adoption is bolstered by a wealth of clinical data supporting its effectiveness, making it a go-to option for practitioners. In contrast, Bone Marrow Aspirate, while considered an emerging segment, is gaining momentum in orthopedic and regenerative medicine practices. Its unique properties allow for the concentration of stem cells along with growth factors, offering promising therapeutic potential. Increased research and a growing body of evidence are enhancing its acceptance, making it a noteworthy alternative in therapeutic applications, particularly when combined with other regenerative techniques. ### By End Use: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the US plasma therapy market, Hospitals hold the largest share, utilizing advanced plasma treatments across various specializations, while Ambulatory Surgical Centers are gaining ground rapidly due to their convenience and lower costs. Clinics also contribute to the market but remain more niche-focused, offering targeted therapies, which limits their overall market share. The growth trend in this segment is driven by increasing demand for outpatient procedures, advancements in plasma therapy technologies, and a growing emphasis on regenerative medicine. Hospitals leverage their established infrastructure to provide comprehensive plasma therapies, while Ambulatory Surgical Centers are being adopted for their efficiency and patient-centric care, leading to a year-on-year rise in their utilization in the market. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals currently dominate the US plasma therapy market as they offer a broader range of services and have higher patient volumes, mainly due to their comprehensive care model. They are equipped with advanced technologies and skilled professionals to conduct complex plasma therapies. On the other hand, Ambulatory Surgical Centers are emerging as a viable alternative for many patients. They provide a cost-effective and convenient solution for outpatient plasma procedures, allowing for faster recovery times and increased patient satisfaction. This trend is likely to evolve as more facilities invest in state-of-the-art equipment to attract patients seeking non-invasive treatment options. ### By Procedure Type: Non-invasive (Largest) vs. Invasive (Fastest-Growing) In the US plasma therapy market, the distribution of procedure types shows a clear dominance of non-invasive procedures, which account for a substantial portion of the market share. These procedures offer patients the dual benefit of efficacy and convenience, allowing them to receive treatment with minimal discomfort and recovery time. In contrast, invasive procedures hold a smaller share but are witnessing rapid growth as advancements in technology enhance their safety and effectiveness. The growth trends in this segment are driven by an increasing consumer preference for non-invasive options due to their lower risk profiles and quicker recovery times. However, the invasive segment is gaining traction as healthcare providers adopt innovative techniques that improve patient outcomes and reduce complications. As a result, the invasive procedures are predicted to grow significantly as they meet the rising demand for more effective therapies. Procedure Type: Non-invasive (Dominant) vs. Invasive (Emerging) The non-invasive procedure type leads in the US plasma therapy market, primarily due to its appealing patient-centric approach. By employing techniques that minimize procedural discomfort and enhance patient convenience, non-invasive methods have become the preferred choice for many. This segment typically includes treatments that leverage advanced technology to achieve desired therapeutic outcomes without the need for surgical interventions. On the other hand, invasive procedures, while currently smaller in market share, represent an emerging segment characterized by rapid innovation. These procedures are increasingly refined through cutting-edge techniques that reduce adverse effects and enhance recovery times, allowing them to position themselves effectively in the market and cater to a niche audience seeking robust treatment options. ## Competitive Benchmarking The plasma therapy market in the US is characterized by a dynamic competitive landscape, driven by increasing demand for innovative treatments and advancements in technology. Key players such as Grifols (Spain), Takeda (Japan), and CSL Behring (Australia) are at the forefront, each adopting distinct strategies to enhance their market presence. Grifols (Spain) focuses on expanding its product portfolio through research and development, while Takeda (Japan) emphasizes strategic partnerships to bolster its therapeutic offerings. CSL Behring (Australia) is known for its commitment to sustainability and operational efficiency, which positions it favorably in a market that increasingly values environmental responsibility. Collectively, these strategies contribute to a competitive environment that is both collaborative and competitive, fostering innovation and growth.In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and enhance responsiveness to market demands. The plasma therapy market appears moderately fragmented, with several key players exerting influence over various segments. This structure allows for a diverse range of products and services, catering to the specific needs of healthcare providers and patients alike. The collective actions of these companies indicate a trend towards optimizing supply chains and enhancing operational efficiencies, which are crucial in maintaining competitive advantage. In October Grifols (Spain) announced a significant investment in a new manufacturing facility in North Carolina, aimed at increasing its production capacity for immunoglobulin therapies. This strategic move is likely to enhance Grifols' ability to meet the growing demand for plasma-derived therapies in the US, thereby solidifying its market position. The investment underscores the company's commitment to innovation and responsiveness to market needs, which may yield substantial long-term benefits. In September Takeda (Japan) entered into a collaboration with a leading biotech firm to develop next-generation therapies utilizing advanced gene editing technologies. This partnership is indicative of Takeda's strategic focus on innovation and its intent to remain at the cutting edge of plasma therapy advancements. By leveraging external expertise, Takeda may enhance its research capabilities and accelerate the development of novel treatments, potentially reshaping its product pipeline. In August CSL Behring (Australia) launched a new sustainability initiative aimed at reducing its carbon footprint by 30% by 2030. This initiative not only reflects the company's commitment to environmental stewardship but also aligns with the growing consumer preference for sustainable practices in healthcare. By prioritizing sustainability, CSL Behring may enhance its brand reputation and appeal to a broader customer base, which is increasingly concerned with corporate responsibility. As of November current trends in the plasma therapy market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in operational processes. Strategic alliances are becoming increasingly pivotal, as companies seek to leverage complementary strengths to drive innovation. The competitive landscape is likely to evolve, with a shift from traditional price-based competition towards differentiation through technological advancements and supply chain reliability. This transition suggests that companies that prioritize innovation and sustainability will be better positioned to thrive in the future. ## Report Scope | MARKET SIZE 2024 | 1183.35(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1293.64(USD Million) | | MARKET SIZE 2035 | 3154.1(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.32% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Grifols (ES), Takeda (JP), CSL Behring (AU), Octapharma (CH), Kedrion (IT), Biotest (DE), LFB (FR), Hualan Biological Engineering (CN) | | Segments Covered | Application, Type, End Use, Procedure Type | | Key Market Opportunities | Advancements in regenerative medicine drive growth in the plasma therapy market through innovative treatment applications. | | Key Market Dynamics | Rising demand for innovative plasma therapies drives competitive dynamics and regulatory scrutiny in the healthcare sector. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US plasma therapy market as of 2024?** A: The US plasma therapy market was valued at $1183.35 Million in 2024. **Q: What is the projected market valuation for the US plasma therapy market in 2035?** A: The projected valuation for the US plasma therapy market in 2035 is $3154.1 Million. **Q: What is the expected CAGR for the US plasma therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US plasma therapy market during the forecast period 2025 - 2035 is 9.32%. **Q: Which application segment had the highest valuation in 2024?** A: In 2024, the dermatology application segment had a valuation of $300 Million. **Q: What are the projected valuations for the Platelet Rich Plasma type by 2035?** A: The projected valuation for the Platelet Rich Plasma type is expected to reach $930 Million by 2035. **Q: Which end-use segment is anticipated to dominate the market by 2035?** A: The hospitals end-use segment, valued at $710 Million in 2024, is anticipated to dominate the market by 2035. **Q: What is the valuation range for the Bone Marrow Aspirate type in 2024?** A: The valuation range for the Bone Marrow Aspirate type in 2024 was between $475.35 Million and $1294.1 Million. **Q: How does the valuation of the non-invasive procedure type compare to invasive procedures in 2024?** A: In 2024, the non-invasive procedure type was valued at $829.35 Million, surpassing the invasive procedure type valued at $354 Million. **Q: Which key players are leading the US plasma therapy market?** A: Key players in the US plasma therapy market include Grifols, Takeda, CSL Behring, and Octapharma. **Q: What is the projected growth trend for the dental application segment by 2035?** A: The dental application segment is projected to grow from $250 Million in 2024 to $700 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-plasma-therapy-market-17651*